GreenLight Clinical – Completed Trials
GreenLight Clinical has managed a range of clinical trials across all phases of development, including post-marketing studies. Having evaluated a host of medications, devices and other therapeutic interventions in over 40 trials, our completed studies include those listed below.
Clinical Trials by Therapeutic Area/Indication
| Ophthamology | Oncology | Haematology | Endocrine | Neurology |
|---|---|---|---|---|
| Glaucoma | Leukaemia | Haemophilia A | Diabetic foot ulcers | Post-herpetic neuralgia |
| Macular Degeneration | Breast Cancer | Type I diabetes | ||
| Macular Oedema | Type 2 diabetes | |||
| Post-surgical inflammation |
Phase I & II Trials
Ophthalmology
- A twelve-month open-label safety study of XXX dosed once-daily in patients with open-angle glaucoma or ocular hypertension
- A Phase I safety, tolerability and efficacy study of XXX versus YYY in the treatment of exudative age-related macular degeneration
- A Phase I safety and efficacy study of XXX versus YYY for the treatment of exudative age-related macular degeneration
- A Phase I randomised, sham-controlled, single ascending dose study to assess the safety, tolerability, and
pharmacokinetic and pharmacodynamic activity of intravitreal XXX in patients with diabetic macular oedema.
- A dose-escalation study of XXX suspension versus YYY for the treatment of exudative age-related macular degeneration
- Efficacy and safety of XXX eye drops (suspension) compared to XXX eye drops (suspension) plus XXX eye drops (solution) in patients with open-angle glaucoma or ocular hypertension
Oncology
- A Phase Ia open-label, dose-ranging, single-centre preliminary trial of the efficacy and safety
of investigative study drug in subjects with ovarian cancer
- A Phase II, randomised, double-blind, multi-centre, placebo-controlled trial of the safety and efficacy of investigative
study drug in patients with leukaemia undergoing BEAM chemotherapy and stem cell transplant
Medical Device
- A placebo-controlled, double-blind, randomised, single-centre, parallel-design study to evaluate the safety
and efficacy of a medical device in the treatment of subjects with ankle sprain injury
Phase III Trials
Ophthalmology
- An evaluation of patient reported outcomes and ocular surface health in patients using XXX eye drops (solution) versus YYY eye drops (solution)
- A Phase IIIB, multicentre, randomised, double-masked, parallel-group, active controlled study of the safety and efficacy of
XXX (QID) and YYY (QID) for the treatment of inflammation following cataract surgery in children 0 to 3 years of age
- A Phase III safety and IOP-lowering efficacy study of XXX/xxx fixed combination eye drops (suspension) compared
to XXX eye drops (suspension) and XXX eye drops (solution) in patients with open-angle glaucoma or ocular hypertension
- A Phase III dose escalation study of XXX suspension versus YYY for the treatment of exudative age-related macular degeneration
- A Phase III prospective, two-cohort, single-masked study to evaluate the effect of XXX applied by XXX injection or infusion
in subjects with exudative age-related macular degeneration
Endocrine/Metabolic System
- A Phase III, multicentre, randomised, double-blind, placebo-controlled study of the safety and efficacy of investigative
study medication in subjects with diabetic foot ulcers
Medical Devices (Ophthalmology – Lens Implantation)
- A randomised, prospective, multicentre, patient-masked, bilateral comparison of XXX implantation versus XXX lens implantation
Nervous System
- A Phase III, multicentre, randomised, double-blind, placebo-controlled evaluation of the safety and efficacy of investigative study medication
in pain treatment of post-herpetic neuralgia (PHN) associated pain
Post-marketing Phase IV Studies
Ophthalmology
- A Phase IV study of XXX versus YYY in patient reported outcomes and ocular surface health
Haematology
- Post-marketing surveillance of investigational product in subjects with severe/moderate Haemophilia A
Medical Devices (Contact Lens):
- Lens wearing experience and biocompatibility of marketed XXX in silicone hydrogel and soft contact lens wearers